These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 3398777)

  • 1. Adverse drug reaction reporting and retrospective phenotyping for oxidation polymorphism.
    Clark DW; Edwards IR
    Med Toxicol Adverse Drug Exp; 1988; 3(3):241-7. PubMed ID: 3398777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population.
    Horai Y; Taga J; Ishizaki T; Ishikawa K
    Br J Clin Pharmacol; 1990 Jan; 29(1):111-5. PubMed ID: 2297455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymorphic oxidation of debrisoquine and sparteine.
    Eichelbaum M
    Prog Clin Biol Res; 1986; 214():157-67. PubMed ID: 3523506
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine.
    Bertilsson L; Dengler HJ; Eichelbaum M; Schulz HU
    Eur J Clin Pharmacol; 1980 Feb; 17(2):153-5. PubMed ID: 7371707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Xenobiotic and endobiotic inhibitors of cytochrome P-450dbl function, the target of the debrisoquine/sparteine type polymorphism.
    Fonne-Pfister R; Meyer UA
    Biochem Pharmacol; 1988 Oct; 37(20):3829-35. PubMed ID: 2903741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions.
    Evans DA; Harmer D; Downham DY; Whibley EJ; Idle JR; Ritchie J; Smith RL
    J Med Genet; 1983 Oct; 20(5):321-9. PubMed ID: 6644761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The debrisoquine/sparteine oxidation polymorphism: evidence of genetic heterogeneity among Ghanaians.
    Woolhouse NM
    Prog Clin Biol Res; 1986; 214():189-206. PubMed ID: 3725761
    [No Abstract]   [Full Text] [Related]  

  • 8. Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities.
    Eichelbaum M; Bertilsson L; Säwe J; Zekorn C
    Clin Pharmacol Ther; 1982 Feb; 31(2):184-6. PubMed ID: 7056024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deficient metabolism of debrisoquine and sparteine.
    Inaba T; Otton SV; Kalow W
    Clin Pharmacol Ther; 1980 Apr; 27(4):547-9. PubMed ID: 7357813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes.
    Otton SV; Crewe HK; Lennard MS; Tucker GT; Woods HF
    J Pharmacol Exp Ther; 1988 Oct; 247(1):242-7. PubMed ID: 3171974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic polymorphism of sparteine/debrisoquine oxidation: a reappraisal.
    Lennard MS
    Pharmacol Toxicol; 1990 Oct; 67(4):273-83. PubMed ID: 2077517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The genetic polymorphism of debrisoquine/sparteine metabolism-molecular mechanisms.
    Meyer UA; Skoda RC; Zanger UM
    Pharmacol Ther; 1990; 46(2):297-308. PubMed ID: 2181495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative pharmacogenetics of sparteine and debrisoquine.
    Inaba T; Vinks A; Otton SV; Kalow W
    Clin Pharmacol Ther; 1983 Mar; 33(3):394-9. PubMed ID: 6825393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism.
    Brøsen K; Klysner R; Gram LF; Otton SV; Bech P; Bertilsson L
    Eur J Clin Pharmacol; 1986; 30(6):679-84. PubMed ID: 3533565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for a dissociation in the control of sparteine, debrisoquine and metoprolol metabolism in Nigerians.
    Lennard MS; Iyun AO; Jackson PR; Tucker GT; Woods HF
    Pharmacogenetics; 1992 Apr; 2(2):89-92. PubMed ID: 1302046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The genetic polymorphism of debrisoquine/sparteine metabolism--clinical aspects.
    Eichelbaum M; Gross AS
    Pharmacol Ther; 1990; 46(3):377-94. PubMed ID: 2188269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of the sparteine/debrisoquine oxidation polymorphism.
    Brøsen K; Gram LF
    Eur J Clin Pharmacol; 1989; 36(6):537-47. PubMed ID: 2570698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic ratios of four probes of CYP2D6 in Turkish subjects: a cross-over study.
    Bozkurt A; Basçi NE; Işimer A; Sayal A; Kayaalp SO
    Eur J Drug Metab Pharmacokinet; 1996; 21(4):309-14. PubMed ID: 9074895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antipyrine metabolism in relation to polymorphic oxidations of sparteine and debrisoquine.
    Eichelbaum M; Bertilsson L; Säwe J
    Br J Clin Pharmacol; 1983 Mar; 15(3):317-21. PubMed ID: 6849767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of the mouse as an experimental model for studying polymorphic oxidation of the sparteine/debrisoquine type.
    Adams M; Lennard MS; Otton SV; Tucker GT; Woods HF
    Biochem Pharmacol; 1991 Jul; 42(4):947-9. PubMed ID: 1867648
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.